Headquartered in Cambridge, MA Fiscal year ends December NASDAQ: BEAM beamtx.com
Beam Therapeutics is a biotechnology company developing precision genetic medicines using its proprietary base editing technology, which enables precise single-base changes at targeted genomic sequences without making double-stranded breaks in DNA. The company has an integrated platform encompassing gene editing, delivery technologies including lipid nanoparticles (LNPs), and internal manufacturing capabilities. Beam's pipeline spans liver-targeted genetic diseases and hematology, with clinical-stage programs including BEAM-302 for alpha-1 antitrypsin deficiency (AATD), risto-cel (formerly BEAM-101) for sickle cell disease, BEAM-301 for glycogen storage disease type Ia, and BEAM-304 for phenylketonuria (PKU). The company is also developing next-generation hematology programs including targeted LNPs for in vivo delivery to hematopoietic stem cells and BEAM-103, an anti-CD117 monoclonal antibody. Beam trades on Nasdaq under the ticker BEAM. Updated
CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would…
A single analyst note sent Kyverna Therapeutics tumbling despite a clinical milestone that had investors cheering just weeks ago, and the question now is whether the selloff marks a buying opportunity or…
The ARK Innovation ETF (NYSEARCA:ARKK) has barely moved this year, gaining about 2% year to date through late June and sitting at roughly $78 per share. That stasis hides a violent tug…
Invasive species represent a $5.4 trillion global problem, with U.S. economic impact alone exceeding $500 billion annually. That’s according to Ben Lamm, CEO of Colossal Biosciences. On episode 245 of the Moonshots…
Wednesday's top analyst upgrades and downgrades included Apple, Boston Scientific, Caterpillar, Ciena, Costco Wholesale, Generac, Hasbro, Rivian Automotive, Steel Dynamics, Tapestry, Trade Desk and Walmart.
Tuesday's top analyst upgrades and downgrades included Adobe, Enterprise Products Partners, Fubo TV, Nvidia, SunPower, Target, Verizon Communications and Walmart.
Friday's top analyst upgrades and downgrades included CenterPoint Energy, Cloudflare, Dynavax Technologies, HCA Healthcare, Opendoor Technologies, Roku, Salesforce.com, Spotify Technology and Wheaton Precious Metals.
One of the hottest recent IPOs, Coinbase, reports June-quarter earnings Tuesday afternoon. Coinbase and three other stocks are held in Cathie Wood's ARK ETFs.
Tuesday's top analyst upgrades and downgrades included Alphabet, Bank of America, Boeing, Coinbase, Dollar General, Kroger and McDonald's.
Monday's top analyst upgrades and downgrades included Apache, CME, Cree, On Semiconductor, Pioneer Natural Resources, Plug Power, Sony and Wayfair.
Tuesday's top analyst upgrades and downgrades included American Express, BlackBerry, BP, CrowdStrike, Noble Midstream, Waste Management and Zscaler.
Friday's top analyst upgrades and downgrades included AGCO, Caterpillar, Chewy, Clorox, Costco Wholesale, First Solar, Netflix, Snap, Starbucks and Wynn Resorts.
The analysts at its underwriting firms are quite positive on Beam Therapeutics, now that its post-IPO quiet period has come to an end.
Jon C. Ogg Monday's top analyst upgrades, downgrades and initiations included ABB, Apple, Baidu, Casper Sleep, General Electric, Groupon, JPMorgan, Micron Technology, PPD, Verizon Communications and Wayfair.
Beam Therapeutics is a biotechnology company developing precision genetic medicines using its proprietary base editing technology, which enables precise single-base changes at targeted genomic sequences without making double-stranded breaks in DNA.
The Wall Street consensus 12-month price target for BEAM is $52.15. BEAM price prediction →
